bluebird bio (BLUE) 2024 Wells Fargo Healthcare Conference summary

Commercial performance and infrastructure

• Three FDA-approved lentiviral gene therapies are on the market, with the latest approved at the end of 2023.

• 70 qualified treatment centers (QTCs) are operational, the largest network in the category.

• Commercial payer coverage now extends to 200 million lives, with Medicaid coverage affirmed in half of U.S. states for sickle cell.

• Cell collection is the key value-creation moment, with 27 collections in the first 7.5 months of 2024 and 40 more scheduled, aiming for 85 by year-end.

• Revenue is recognized at infusion, typically about a month after product shipment.

Product launches and market dynamics

• Sickle cell therapy (Lyfgenia) is the largest product, with initial launch slower than expected but ramping in the second half of the year.

• About one-third of eligible sickle cell patients are ready for gene therapy soon, with another third considering it in the next few years.

• Fertility preservation and black box warnings are considerations, but QTCs and insurance often help navigate these issues.

• Lyfgenia is preferred in recent market research due to its mechanism, data, and logistics.

• Beta thalassemia therapy (Zynteglo) shows steady linear growth, with recent capacity expansion to meet demand.

Operational and financial updates

• Manufacturing turnaround for sickle cell therapy is up to 105 days, with capacity sufficient for current demand and plans to scale as needed.

• Insurance coverage for therapies is strong, with no denials for earlier products and high success for Lyfgenia.

• Restatement of financials is underway due to historical lease accounting, expected to be completed soon.

• Cash runway extends into Q2 2025, but additional capital is needed before then; multiple financing options are being explored.

• Access to further Hercules Capital tranches depends on raising additional funds and meeting patient milestones.